Fulcrum Therapeutics
- Founded: 2016
- Location: Cambridge, MA
- Employee range: 50 - 200
- Clinical stage: Clin3
- Therapy area: Facioscapulohumeral muscular dystrophy
- Drug types: RAR, MUS, GEN, HEM, NEU, CVV
- Lead product: Losmapimod
- Product link: https://www.fulcrumtx.com/pipeline/
- Funding: $125M stock Jan 2023; $144M stock Aug 2021; $68.5M private placement Jun 2020; $72M IPO Jul 2019; $80M B Sep 2018; $55M A Jul 2016
fulcrumtx.com linkedin.com job board
Short description:
Unlocking gene control mechanisms to develop small molecule therapies
Drug notes:
FTX-6058 Clin1b (clinical hold Feb 2023) sickle cell disease; 4 undisclosed programs RD/Clin0 blood disorders, neurologic disorders, muscle disorders, cardiomyopathies
Long description:
Fulcrum therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined diseases. Inspired by patients, Fulcrum drug discovery begins with a deep exploration of disease biology in patient tissue samples. Fulcrum’s proprietary annotated compound library enables them to systematically approach drug discovery in genetically defined diseases. Drug targets are identified that modify gene expression and analyzed computationally using their proprietary database, FulcrumSeek. Fulcrum’s lead program, losmapimod, is being investigated in clinical trials to beat facioscapulohumeral muscular dystrophy.
© 2023 Work In Biotech LLC
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com